Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD1613 in Healthy Participants
NCT06995820Phase 1Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Jun 2025
- Primary completion
- Nov 2026
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of AZD1613 (13 arms), sponsored by AstraZeneca. Primary endpoint: Number of participants with adverse events (AEs) and serious AEs. Started Jun 2025; status: active, not recruiting.
02
Drugs
AZD1613
Beyond the preview
Go deeper on NCT06995820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06995820.